Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β

Simpson-Yap, Steve; Pirmani, Ashkan; De Brouwer, Edward; Peeters, Liesbet; Geys, Lotte; Parciak, Tina; Helme, Anne; Hillert, Jan; Moreau, Yves; Edan, Gilles; Spelman, Tim; Sharmin, Sifat; McBurney, Robert; Schmidt, Hollie; Bergmann, Arnfin; Braune, Stefan; Stahmann, Alexander; Middleton, Rodden; Salter, Amber; Bebo, Bruce; van der Walt, Anneke; Butzkueven, Helmut; Ozakbas, Serkan; Karabudak, Rana; Boz, CAVİT; Alroughani, Raed; Rojas, Juan; van der Mei, Ingrid; Sciascia do Olival, Guilherme; Magyari, Melinda; Alonso, Ricardo; Nicholas, Richard; Chertcoff, Anibal; Zabalza, Ana; Arrambide, Georgina; Nag, Nupur; Descamps, Annabel; Costers, Lars; Dobson, Ruth; Miller, Aleisha; Rodrigues, Paulo; Prčkovska, Vesna; Comi, Giancarlo; Kalincik, Tomas

doi:10.1016/j.msard.2022.104072

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β

Atıf İçin Kopyala

Simpson-Yap S., Pirmani A., De Brouwer E., Peeters L. M., Geys L., Parciak T., ...Daha Fazla

Multiple Sclerosis and Related Disorders, cilt.66, 2022 (SCI-Expanded)

Yayın Türü: Makale / Kısa Makale
Cilt numarası: 66
Basım Tarihi: 2022
Doi Numarası: 10.1016/j.msard.2022.104072
Dergi Adı: Multiple Sclerosis and Related Disorders
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

© 2022 Elsevier B.V.Background: Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS. Results: Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs. Conclusions: In comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-β. This study does not support the use of interferon-β as a treatment to reduce COVID-19 severity in MS.